Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 32Colorectal Neoplasms 8Brain Neoplasms 7Stomach Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 3Meningeal Neoplasms 3HER2-positive Breast Cancer 3Rectal Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Colonic Neoplasms 2Adenocarcinoma Of Esophagus 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Metastatic Breast Cancer With a Isolated Brain Progression 1Meningeal Carcinomatosis 1Lung Neoplasms 1Hemangiosarcoma 1HER2-positive Metastatic Breast Cancer 1HER2-positive Gastric Cancer 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Central Nervous System Diseases 1

Interventions

Paclitaxel 13pembrolizumab 8Carboplatin 7Cisplatin 5Docetaxel 4Brachytherapy 4Pemetrexed 3Gemcitabine 3Doxorubicin 3Biopsy 3osimertinib 2olaparib 2niraparib 2durvalumab 2adavosertib 2Trastuzumab 2Topotecan 2Taxes 2Standard of Care 2Sentinel Lymph Node Biopsy 2Saline Solution 2Radiotherapy 2Radiation 2Oxaliplatin 2Nivolumab 2Music Therapy 2Magnetic Resonance Spectroscopy 2Leucovorin 2Letrozole 2Immunoglobulin G 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Uterine Neoplasms × tucatinib × Clear all
NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Seagen Inc.

Phase 2 Active not recruiting
217 enrolled 19 charts
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡